Condition: Non-Hodgkin's Lymphoma (disorder) · Acute Lymphoid Leukemia, Disease (disorder) · Sponsor: Chimagen Biosciences, Ltd
This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Yale New Haven Hospital | New Haven, Connecticut, United States | — |
| Norton Cancer Institute | Louisville, Kentucky, United States | — |
| UPMC CancerCenter | Pittsburgh, Pennsylvania, United States | — |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
| Froedtert & the Medical College of Wisconsin Froedtert Hospital | Milwaukee, Wisconsin, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05348889